ПОЛУЧЕНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ РЕЦЕПТОРА ТИРЕОТРОПНОГО ГОРМОНА И ТИРЕОПЕРОКСИДАЗЫ ЧЕЛОВЕКА

1. Smith T.J.TSHR as a therapeutic target in Graves' disease. Expert Opin Ther Targets. 2017;21(4): 427-432.

2. Rapoport B., McLachlan S.M.TSH receptor cleavage into subunits and shedding of the A-subunit; a molecular and clinical perspective. Endocrine Reviews. 2016;37(2): 114-34.

3. Sanders J., Bolton J., Sanders P., Jeffreys J., Nakatake N., Richards T., Evans M., Kiddie A., Summerhayes S., Roberts E., Miguel R.N., Furmaniak J., Smith B.R. Effects ofTSH receptor mutations on binding and biological activity of monoclonal antibodies andTSH. Thyroid. 2007;17(2): 1195-1206.

4. Furmaniak J., Sanders J., Núñez Miguel R., B. Rees Smith. Mechanisms of Action of TSHR Autoantibodies. Horm Metab Res. 2015;47: 735-752.

5. Parmentier M., Libert F., Maenhaut C., Lefort A., Gerard C., Perret J., Van Sande J., Dumont J.E., Vassart G. Molecular cloning of the thyrotropin receptor. Science. 1989;246(4937): 1620-1622.

6. Gardas A., Watson P.F., Hobby P., Smith A., Weetman A.P., Sutton, B.J. and Banga J.P. Human thyroid peroxidase: mapping of autoantibodies, conformational epitopes to the enzyme surface. Redox. Rep., 2000, 5, p. 237-241